...
首页> 外文期刊>Genetic Engineering & Biotechnology News: The Information Source of the Biotechnology Industry >Transforming Inflammatory Disease Therapies: Amira's Expertise Lies in Once-Daily Oral Therapies Targeting Bioactive Lipids
【24h】

Transforming Inflammatory Disease Therapies: Amira's Expertise Lies in Once-Daily Oral Therapies Targeting Bioactive Lipids

机译:改变炎症性疾病疗法:Amira的专长在于针对生物活性脂质的每日口服疗法

获取原文
获取原文并翻译 | 示例
           

摘要

When Merck closed its San Diego operations in 2005, a team of about 20 scientists all experienced in developing drugs in the bioactive-lipid space, moved to the newly formed Amira Pharmaceuticals (www.amirapharm. com), founded by Peppi Prasit, Ph.D.,Jilly Evans, Ph.D., and John Hutchinson, Ph.D. The Merck scientists played important roles in developing a number of anti-inflammatory drugs including Singular~R.
机译:默克公司于2005年关闭其在圣地亚哥的业务时,一支由大约20位在生物活性脂质领域开发药物经验丰富的科学家组成的团队转移到了由Peppi Prasit,Ph。 D.,Jilly Evans博士和John Hutchinson博士默克的科学家在开发包括Singular®R在内的多种抗炎药中发挥了重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号